Scarica l'app Stockscreener
18.94
2.99%
0.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis Pharmaceuticals (APLS) Receives Buy Rating Amid Growth P - GuruFocus
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts - Stock Titan
APLS: Roth Capital Initiates Coverage with 'Buy' Rating at $31.00 | APLS Stock News - GuruFocus
Apellis stock wins new Buy at Roth on Syfovre (APLS:NASDAQ) - Seeking Alpha
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS) - Finviz
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors - simplywall.st
Apellis Pharmaceuticals Balances Growth With Revenue Headwinds - The Globe and Mail
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN
Apellis Adds Ex Pfizer R&D Chief To Board As Growth Plans Evolve - Sahm
(APLS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JP Morgan Raises Price Target for APLS, Maintains Overweight Rat - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co. - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $20.00 at Mizuho - MarketBeat
APLS: Mizuho Maintains Rating, Raises Price Target | APLS Stock News - GuruFocus
Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts - Benzinga
APLS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Update Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Apellis Pharmaceuticals (APLS) director receives new stock options and RSUs - Stock Titan
Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing - Stock Titan
Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 62.73% Upside Potential in Biotech - DirectorsTalk Interviews
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. - MarketBeat
Apellis adds former Pfizer research chief to board - Investing.com
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors - Investing.com Australia
Apellis Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Vanguard Group Inc. - MarketBeat
Apellis Pharmaceuticals Adds Mikael Dolsten to Board - TipRanks
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors By Investing.com - Investing.com India
Apellis adds former Pfizer research chief to board By Investing.com - Investing.com Canada
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Bitget
Mikael Dolsten joins Apellis Board as Class I director - TradingView
Mikael Dolsten joins Apellis (NASDAQ: APLS) board with equity grants - Stock Titan
Pfizer veteran who led R&D for 16 years joins Apellis board - Stock Titan
A Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook - simplywall.st
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright Issues Optimistic Outlook for APLS Earnings - MarketBeat
Assessing Apellis Pharmaceuticals (APLS) Valuation After Prolonged Share Price Weakness - Yahoo Finance
Apellis (APLS) Q4 2025 Earnings Call Transcript - AOL.com
Analysts Issue Forecasts for APLS FY2030 Earnings - MarketBeat
Apellis price target lowered to $18 from $20 at Wedbush - Yahoo Finance
Apellis Pharmaceuticals Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo
RBC Capital Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS) - The Globe and Mail
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
S&E In Brief: Commercial Updates From The SMID Cap Universe - Citeline News & Insights
RBC Capital Adjusts Price Target for Apellis Pharmaceuticals (AP - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $44.00 by Analysts at Citigroup - MarketBeat
APLS: Citigroup Maintains Rating, Lowers Price Target to $44.00 - GuruFocus
Mizuho Securities Adjusts Apellis Pharmaceuticals PT to $20 From $19, Maintains Neutral Rating - marketscreener.com
Royal Bank Of Canada Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $21.00 - MarketBeat
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y - Yahoo Finance
Why Apellis Pharmaceuticals Stock Is Under Pressure - TipRanks
RBC Capital Adjusts Apellis Pharmaceuticals PT to $21 From $22, Maintains Sector Perform Rating - marketscreener.com
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $18.00 at Wedbush - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
APLS: Analyst Wedbush Lowers Price Target to $18 While Maintaini - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright raises Apellis stock price target on Syfovre outlook - Investing.com Australia
HC Wainwright & Co. Raises Price Target for APLS to $48.00 | APLS Stock News - GuruFocus
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Apellis Pharmaceuticals Inc (APLS) Q4 2025 Earnings Call Highlig - GuruFocus
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):